Evidence map›Paper›PMID 41123746›Full record

ArticleDiscover oncology2025

Peripheral SNCA

Chie Kudo-Saito, Hiroshi Imazeki, Kengo Nagashima, Hirokazu Shoji, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chie Kudo-SaitoDepartment of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp.
Hiroshi ImazekiDepartment of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Kengo NagashimaBiostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Hirokazu ShojiDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kai TsugaruDivision of Gastroenterology and Hepatology, Keio University Hospital, Tokyo, Japan.
Naoki TakahashiDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Takeshi KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yusuke AmanumaClinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
Takeru WakatsukiDepartment of Gastrointestinal Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Yukiya NaritaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Yoshiyuki YamamotoDepartment of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan.
Rika KizawaDepartment of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Narikazu BokuDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Funding

Bristol-Myers Squibb A2018-032Ono Pharmaceutical A2018-032
6 · The paper itself

Abstract

backgroundWe previously demonstrated that immune cells expressing α-synuclein (SNCA) are dramatically increased in peripheral blood of patients with gastric cancer (GC), but rarely in healthy donors, and that blocking SNCA is significantly effective even in anti-PD1-resistant mouse tumor models with increased SNCA

methodsIn the WJOG10417GTR study, peripheral blood cells collected from advanced GC patients before and one month after nivolumab monotherapy were analyzed for several SNCA

resultsHigh levels of SNCA

conclusionThese suggest that SNCA

Indexed as

BiomarkerGastric cancerImmune checkpointPD1SNCA

Identifiers

PMID41123746
PMCPMC12546165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.